secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001104659-25-075175
Event type: earnings
Sentiment:  neutral
Materiality: 0.90
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Iovance reports Q2 2025 earnings: $60M revenue, appoints new CFO, extends cash runway into Q4 2026
--------------------------------------------------------------------------------

- Q2 2025 total product revenue $60.0M (Amtagvi $54.1M, Proleukin $5.9M), net loss $111.7M.
- Reiterated FY2025 total product revenue guidance of $250M-$300M.
- Appointed Corleen Roche as CFO, effective after Q2 10-Q filing, replacing Matthew Rosinack.
- Strategic restructuring reduces workforce by 19%, generating over $100M annual savings, extending cash runway into Q4 2026.
- Over 100 patients treated with Amtagvi in Q2; network includes over 80 ATCs across 35 states.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/0001104659-25-075175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925075175/tm2522769d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-075175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer